An investigation for investors in Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares over potential securities laws violations by Milestone Pharmaceuticals Inc. was announced.

Milestone Pharmaceuticals Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Milestone Pharmaceuticals Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Montreal, Canada based Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. On or about May 9, 2019, Milestone Pharmaceuticals Inc. sold about 5.5 million shares of stock in its initial public stock offering (the "IPO"), at $15.00 a share raising approximately $82,500,000 in new capital.

On December 26, 2023, Milestone Pharmaceuticals Inc announced that it had received a Refuse to File ("RFT") letter from the U.S. Food and Drug Administration ("FDA") for its recently submitted New Drug Application ("NDA") for its lead candidate, Etripamil, a self-administered nasal spray for the treatment of paroxysmal supraventricular tachycardia. The Company advised that, in the RFT, the FDA had "determined that the NDA, submitted in October 2023, was not sufficiently complete to permit substantive review" and "requested clarification about the time of data recorded for adverse events in Phase 3 clinical trials".

Shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) declined from $1.33 per share on January 22, 2024.

Those who purchased shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.